AEON Biopharma (NASDAQ:AEON) Stock Price Down 2.5% – Here’s Why

AEON Biopharma, Inc. (NASDAQ:AEON) traded down 2.5% on Friday . The company traded as low as $1.14 and last traded at $1.16. 92,931 shares changed hands during trading, a decline of 67% from the average session volume of 278,212 shares. The stock had previously closed at $1.19.

Analysts Set New Price Targets

AEON has been the topic of a number of research reports. Zacks Research upgraded AEON Biopharma to a “hold” rating in a research report on Tuesday, November 18th. Aegis reaffirmed a “buy” rating on shares of AEON Biopharma in a report on Wednesday, October 8th. Finally, HC Wainwright raised AEON Biopharma to a “strong-buy” rating in a report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, AEON Biopharma currently has an average rating of “Buy”.

AEON Biopharma Stock Down 2.5%

The business’s fifty day moving average price is $1.01 and its 200 day moving average price is $0.90. The firm has a market capitalization of $13.73 million, a PE ratio of 6.44 and a beta of 0.72.

AEON Biopharma Company Profile

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.